Pulmonary embolism (PE) in the context of coronavirus disease 2019 (COVID-19) appears to be driven largely by inflammation and coagulopathy rather than by traditional risk factors for thromboembolism.

Study results suggest that anticoagulation therapy with prophylactic dosing during hospitalization or therapeutic dosing before admission could reduce occurrence of PE.

Findings are consistent with international guidelines, which recommend prophylactic anticoagulation, unless contraindicated, for hospitalized adult and adolescent patients with COVID-19.

The retrospective, observational Critical Covid-19 France study evaluated consecutive adult patients diagnosed with severe acute respiratory syndrome coronavirus 2 who were admitted to any of 24 hospitals in France between February 26 and April 20, 2020.

Read More